Work

Safety of Lisocabtagene Maraleucel Given With Durvalumab in Patients With Relapsed/refractory Aggressive B‐cell Non Hodgkin Lymphoma: First Results From the Platform Study

Year: 2019

Type: article

Study design: Clinical Trial

Source: Hematological Oncology

DOI: 10.1002/hon.128_2629

Authors: T. Siddiqi, J.S. Abramson, H.J. Lee, S. Schuster, J. Hasskarl, S. Montheard, J. Dell Aringa, E. Thompson, R. Ananthakrishnan, M. Lunning

Institutions: City Of Hope National Medical Center, Massachusetts General Hospital, The University of Texas MD Anderson Cancer Center, Abramson Cancer Center, Celgene (Switzerland), Juno Therapeutics (United States), Celgene (United States), University of Nebraska Medical Center

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2949916213

FWCI: 1.538

Cites:

Cited by: 34

Related to: 10